Last updated: March 2026
Follistatin-344 is a 344-amino acid glycoprotein that binds and neutralizes myostatin — the body's primary genetic limiter of skeletal muscle growth. It also blocks activin-A and other TGF-β family members involved in muscle wasting. Gene therapy research suggests remarkable potential; peptide administration is far less dramatic but of significant interest in the athletic community.
Before follistatin made headlines, myostatin had to be discovered. The story starts with extraordinarily muscular mice — and cattle that looked like they were carved from stone.
Alexandra McPherron and Se-Jin Lee at Johns Hopkins published a landmark paper in Nature describing a new TGF-β superfamily member they named GDF-8 (myostatin). Mice with the myostatin gene knocked out developed 2–3× normal muscle mass with virtually no fat accumulation. The animals were healthy and fertile. Myostatin was immediately recognized as the master brake on skeletal muscle growth.
The Belgian Blue and Piedmontese cattle breeds exhibit extreme muscularity from natural loss-of-function mutations in the myostatin gene. Belgian Blues show double muscling — an estimated 20–40% more muscle mass than unaffected breeds. These animals validated the mouse findings: blocking myostatin, naturally or pharmacologically, produces dramatic muscle hyperplasia and hypertrophy.
Schuelke et al. (NEJM 2004) reported the first documented case of myostatin deficiency in a human child. At age 4, the child could hold two 3-kg dumbbells horizontally with extended arms — feats not seen in children. Genetic testing confirmed a mutation in the myostatin gene. The child was extraordinarily muscular with exceptionally low body fat, apparently healthy, raising intense interest in therapeutic myostatin inhibition.
Se-Jin Lee's group at Johns Hopkins delivered a follistatin gene construct (AAV1-FS344) to non-human primates. Over 15 months, treated animals showed approximately double the muscle mass in targeted muscle groups with no adverse health effects. This was the critical bridge study enabling human trials. The finding was extraordinary: sustained follistatin expression via gene therapy produced results far beyond what any peptide injection protocol has ever replicated.
Jerry Mendell's team at Nationwide Children's Hospital (NCH) published results of the first human follistatin gene therapy trial in Annals of Clinical and Translational Neurology (2015). Six patients with Becker muscular dystrophy received intramuscular AAV1-FS344. The study showed improved muscle performance on the six-minute walk test at 12 months in several patients. No serious adverse events attributable to the gene therapy. A critical step — but gene therapy, not peptide injection.
Follistatin-344 is a high-affinity binding protein for myostatin and activin — two TGF-β superfamily ligands that suppress muscle growth. By neutralizing them, it removes the molecular brakes on skeletal muscle hypertrophy.
Myostatin binds ActRIIB receptors on muscle cells, activating SMAD2/3 signaling that suppresses protein synthesis and satellite cell activation. Follistatin-344 binds myostatin with extremely high affinity, sequestering it before it reaches its receptor — effectively turning off the muscle growth brake.
Activin-A (a related TGF-β family member) also signals through ActRIIB, suppressing muscle growth and contributing to muscle wasting in disease states. Follistatin-344 binds activin-A with similar affinity to myostatin. This activin blockade has downstream consequences for FSH secretion — relevant for reproductive safety.
Both myostatin and activin-A signal through the Activin Receptor Type IIB (ActRIIB). By binding these ligands, follistatin leaves ActRIIB unoccupied — freeing it for pro-anabolic signaling from BMP ligands (like BMP7) while blocking the anti-anabolic inputs. Net effect: shifted muscle signaling balance toward growth.
Myostatin normally suppresses satellite cell (muscle stem cell) proliferation and self-renewal. When follistatin neutralizes myostatin, satellite cells become more responsive to hypertrophic stimuli — increasing the pool of myogenic precursors available for muscle repair and growth after exercise or injury.
Myostatin/SMAD3 signaling suppresses mTORC1 activity, limiting protein synthesis rates. Follistatin-mediated myostatin blockade removes this suppression, allowing mTORC1 and its downstream targets (S6K1, 4E-BP1) to operate at higher capacity in response to training and nutritional signals.
Follistatin exists in two primary isoforms: FS-288 and FS-344. FS-288 is largely heparin-bound and stays local to tissues. FS-344 has reduced heparin-binding affinity, allowing it to circulate systemically. This makes FS-344 the preferred isoform for research applications where systemic bioavailability is desired.
The key distinction: Follistatin-344 doesn't directly stimulate muscle growth — it removes the inhibition of muscle growth. This is mechanistically different from anabolic agents like testosterone, IGF-1, or GH, which directly activate growth pathways. Follistatin works by unblocking the brake, allowing the body's own growth machinery to operate without restriction.
The evidence base is strong for the mechanism and compelling in animal models. Human clinical data is limited to gene therapy trials in diseased populations — not healthy individuals.
Follistatin-344 is widely discussed in performance-enhancement circles. The hype far outpaces the evidence. Here's an honest assessment.
Bottom line for performance use: The mechanistic rationale is sound — myostatin genuinely limits muscle growth, and follistatin genuinely neutralizes myostatin. However, peptide-based FS-344 protocols have no controlled human efficacy data. Anecdotal reports in the bodybuilding community suggest modest-to-moderate effects. The extreme gains seen in animal gene therapy studies will not be replicated by SubQ peptide injections — the pharmacokinetics are fundamentally different.
Transiently elevating circulating follistatin via peptide injection should, in principle, partially neutralize systemic myostatin. This could reduce the negative anabolic signal during training windows. The effect would be dose- and timing-dependent, and likely modest compared to gene therapy.
No controlled trials show significant muscle mass or strength increases from SubQ FS-344 peptide in healthy humans. Claims of "20 lbs of muscle in a cycle" are not supported by published data. The peptide's half-life is short; sustained myostatin suppression requires either gene therapy or extremely frequent dosing.
The mechanism is unambiguously real. Myostatin is a genuine brake on muscle growth. The gene therapy results are extraordinary. For individuals who have "maxed out" what traditional anabolics can do, partial myostatin inhibition via peptide remains an intellectually interesting approach — even without robust efficacy data.
In stacks, FS-344 is often combined with anabolic agents (MK-677, RAD-140, or testosterone) with the theoretical goal of combining direct anabolic stimulation with myostatin relief. The synergy is theoretically rational but unvalidated in human trials.
The following reflects community research protocols. No controlled human clinical trials establish optimal dosing for FS-344 peptide. These are not recommendations.
| Parameter | Typical Research Protocol | Notes |
|---|---|---|
| Dose Range | 50–200 mcg/day | Most commonly reported: 100 mcg/day. Higher doses increase cost and theoretical risk with uncertain benefit. |
| Cycle Length | 10 days on, 3–4 weeks off | Short cycles are standard due to cost and theoretical receptor sensitivity concerns. Not a continuous compound. |
| Route | Subcutaneous (SubQ) injection | Oral administration is ineffective — peptide is degraded by proteases in the GI tract. Intramuscular also used by some. |
| Injection Site | Abdomen, thigh, or target muscle | Some protocols advocate injecting near the target muscle group to achieve localized effect, though systemic distribution occurs. |
| Needle | 29–31G insulin syringe | Standard insulin syringe. Short needle (5/16" or 8mm) appropriate for SubQ. |
| Reconstitution | Bacteriostatic water (BW) | Typically reconstituted to 1mg/mL with bacteriostatic water. Store reconstituted solution at 4°C, use within 30 days. |
| Timing | Pre-training or AM fasted | No strong pharmacokinetic rationale for specific timing; AM pre-workout is common community practice. |
| Half-Life (peptide) | ~1–3 hours (estimated) | Follistatin peptide is rapidly degraded in vivo. Gene therapy results are not achievable because sustained expression cannot be replicated by peptide injection. |
| Cycling | 10 days on / 3–4 weeks off | Often run 1–2 times per quarter. Some protocols use "blast" during competition prep or high-volume training blocks. |
| Common Stack | MK-677, RAD-140, or GH peptides | Frequently combined with anabolic compounds — theoretical synergy of removing myostatin brake while activating growth pathways. |
Cost note: Follistatin-344 is among the most expensive research peptides — typically $300–600+ per 1mg vial depending on the source. A 10-day cycle at 100mcg/day requires 1mg, making regular cycling extremely costly. This limits its use primarily to advanced, high-budget researchers.
New clinical applications are putting myostatin inhibition back in the spotlight — from muscular dystrophy to preventing GLP-1-induced muscle wasting.
The Mendell 2015 study used AAV1-delivered follistatin gene therapy in patients with Becker muscular dystrophy. Results: statistically significant improvement in the 6-minute walk test — a validated functional measure of muscle capacity. Patients showed sustained follistatin expression and measurable functional gains at 12-month follow-up. This remains the most rigorous human evidence for myostatin inhibition's therapeutic potential.
Here's why follistatin research is gaining renewed interest: 20-40% of weight loss from GLP-1 agonists (semaglutide, tirzepatide) is lean mass — not fat. That's a significant amount of muscle being sacrificed for weight loss. Myostatin inhibition, including follistatin, is being discussed as a theoretical counter-strategy to preserve lean mass during aggressive weight loss protocols. No direct trial data yet, but the mechanistic rationale is strong.
Important distinction: Gene therapy delivers continuous, high-level follistatin expression directly to muscle tissue via viral vector. Subcutaneous peptide injection cannot replicate this — FS-344 peptide has a ~1-3 hour half-life and systemic distribution. The dramatic gene therapy results (doubled muscle mass in primates) should not be expected from peptide protocols. Different delivery = different magnitude of effect.
Follistatin-344's safety profile in humans is poorly characterized. The mechanistic concerns are significant — especially around reproductive function and theoretical tumor risk.
Given the evidence gaps and real mechanistic risks, Follistatin-344 is appropriate only for a narrow, well-informed research context.
Baseline testing recommendation: If considering FS-344 research, establish baseline FSH, LH, testosterone, and CBC before starting. Monitor FSH during and after cycles. Any significant FSH suppression should be taken seriously as a signal to discontinue.
Follistatin-344 is often considered alongside these compounds — each with distinct mechanisms, evidence bases, and risk profiles.
Oral GH secretagogue. ~40% IGF-1 increase. Complementary to FS-344: activates growth axis while FS-344 removes myostatin brake. Oral, 10-25mg daily.
90:1 anabolic:androgenic ratio — most potent SARM. Direct AR activation for muscle growth. Often stacked with FS-344 for complementary mechanisms.
Unique dual mechanism: SARM + induces endogenous follistatin expression to inhibit myostatin. Steroidal structure. Cell study data only.
Well-studied SARM with Phase 2 human trial data. 1mg/day produced 1.21 kg lean mass over 21 days. Strongest clinical data among SARMs.
25–40% of GLP-1 weight loss is muscle. FS-344 is a theoretical counter-strategy for those on semaglutide — but no direct data exists.
Our original Follistatin-344 overview page — shorter format covering the basics of myostatin inhibition and gene therapy research.
Essential supplies for research peptide protocols and muscle optimization.
Affiliate links help support MeetPeptide at no extra cost to you.
Dosing schedules, interaction warnings, and cycle protocols for 50+ compounds — all in one place.
This page is for educational and informational purposes only. Follistatin-344 is a research compound not approved by the FDA or any regulatory body for human use. All data presented comes from animal studies, gene therapy clinical trials, or is extrapolated from published research — not from controlled human peptide administration trials. The extreme muscle mass increases reported in animal models and gene therapy studies are not expected from SubQ peptide injection protocols. Safety data for human peptide use is essentially nonexistent. This compound carries real mechanistic risks including reproductive hormone disruption and theoretical tumor concerns. Always consult a qualified, licensed healthcare provider before starting any new compound. Nothing on this page constitutes medical advice.